• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在常规实践中通过高危型 HPV 检测进行宫颈癌筛查:高危型 HPV 阳性和细胞学阴性女性一年随访的结果。

Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.

机构信息

Immunology and Molecular Oncology Unit, Veneto Oncology Institute IOV IRCCS, Padova, Italy.

出版信息

J Med Screen. 2014 Mar;21(1):30-7. doi: 10.1177/0969141314522219. Epub 2014 Jan 31.

DOI:10.1177/0969141314522219
PMID:24488593
Abstract

OBJECTIVE

Cervical cancer screening by human papillomavirus (HPV) testing requires the use of additional triage and follow-up analyses. We evaluated women's compliance with and the performance of this strategy in a routine setting.

SETTING

Five cervical service screening programmes in North-East Italy.

METHODS

Eligible women aged 25-64 invited for a new screening episode underwent HPV testing for high risk types (hrHPV by Hybrid Capture 2) and cytology triage. Women with positive HPV and cytology results were referred for colposcopy; women with positive HPV but negative cytology results were referred to 1-year repeat hrHPV testing.

RESULTS

Of 46,694 women screened by HPV testing up to December 2011, 3,211 (6.9%) tested hrHPV positive; 45% of these had a positive triage cytology. Those with negative cytology were invited for 1-yr repeat testing. Compliance with invitation was 61.6% at baseline and 85.3% at 1-yr repeat. Rate of persistent hrHPV positivity was 58% (830/1,435). Colposcopy performed in women with a positive hrHPV test at 1-yr repeat accounted for 36% of all colposcopies performed within the screening programmes. Cumulatively, a histological high-grade lesion was detected in 276 women (5.9‰ detection rate), 234 at baseline (85%), and 42 (15%) at 1-yr repeat.

CONCLUSIONS

Compliance with hrHPV-based screening programmes was high both at baseline and at 1-yr repeat. Compared with the randomized trials, a higher proportion of triage cytology was read as positive, and only a small number of high-grade lesions were detected among the group of hrHPV positive cytology negative women who repeated testing 1-yr after baseline.

摘要

目的

人乳头瘤病毒(HPV)检测的宫颈癌筛查需要额外的分流和随访分析。我们在常规环境中评估了女性对该策略的依从性及其性能。

地点

意大利东北部的 5 个宫颈服务筛查计划。

方法

邀请新筛查的年龄在 25-64 岁之间的合格女性进行高危型 HPV(杂交捕获 2 型的 HPV)和细胞学分流检测。HPV 和细胞学阳性的女性被转诊行阴道镜检查;HPV 阳性而细胞学阴性的女性被转诊行 1 年重复的高危型 HPV 检测。

结果

截至 2011 年 12 月,对 46694 名接受 HPV 检测的女性进行筛查,其中 3211 名(6.9%)检测出高危型 HPV 阳性;其中 45%的细胞学分流检测呈阳性。细胞学阴性的女性被邀请进行 1 年重复检测。基线时的邀请依从率为 61.6%,1 年重复时的依从率为 85.3%。持续 HPV 阳性的发生率为 58%(830/1435)。在 1 年重复时 HPV 检测阳性的女性中,进行阴道镜检查占筛查计划中所有阴道镜检查的 36%。累计发现 276 名(5.9‰检出率)女性有组织学高级别病变,其中 234 名(85%)在基线时发现,42 名(15%)在 1 年重复时发现。

结论

HPV 检测的宫颈癌筛查的基线和 1 年重复的依从率均较高。与随机试验相比,细胞学分流检测的阳性率更高,并且在基线后 1 年重复检测 HPV 阳性而细胞学阴性的女性中,仅发现少数高级别病变。

相似文献

1
Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.在常规实践中通过高危型 HPV 检测进行宫颈癌筛查:高危型 HPV 阳性和细胞学阴性女性一年随访的结果。
J Med Screen. 2014 Mar;21(1):30-7. doi: 10.1177/0969141314522219. Epub 2014 Jan 31.
2
Human papillomavirus test with cytology triage in organized screening for cervical cancer.在宫颈癌组织筛查中采用人乳头瘤病毒检测及细胞学分流
Acta Obstet Gynecol Scand. 2016 Nov;95(11):1220-1227. doi: 10.1111/aogs.13013.
3
Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland.宫颈癌的原发性人乳头瘤病毒筛查:芬兰一项区域筛查项目两轮筛查后的结果
Acta Obstet Gynecol Scand. 2021 Mar;100(3):403-409. doi: 10.1111/aogs.14021. Epub 2020 Oct 30.
4
Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.高危型人乳头瘤病毒 DNA 检测作为宫颈癌筛查计划中的主要检测方法:一项基于人群的队列研究。
BJOG. 2013 Sep;120(10):1260-7; discussion 1267-8. doi: 10.1111/1471-0528.12272. Epub 2013 Jun 21.
5
HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.基于人群的宫颈癌筛查中 HPV DNA 检测(VUSA-Screen 研究):结果与意义。
Br J Cancer. 2012 Feb 28;106(5):975-81. doi: 10.1038/bjc.2011.581. Epub 2012 Jan 17.
6
Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.在随机环境中对原发性人乳头瘤病毒筛查与传统细胞学进行特定年龄评估。
J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.
7
Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.西班牙加泰罗尼亚地区,在诊断出非典型鳞状细胞意义不明确(ASC-US)后,利用 HPV DNA 检测对宫颈上皮内瘤变 2+(CIN2+)进行预测。
BMC Infect Dis. 2012 Jan 26;12:25. doi: 10.1186/1471-2334-12-25.
8
The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.英格兰原发性人乳头瘤病毒子宫颈筛查的临床效果和成本效益:通过三轮筛查对 ARTISTIC 随机试验队列进行的扩展随访。
Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.
9
Clinical performance of human papillomavirus based cervical cancer screening algorithm: The result of a large Danish implementation study.基于人乳头瘤病毒的宫颈癌筛查算法的临床性能:一项大型丹麦实施研究的结果。
Acta Obstet Gynecol Scand. 2024 Sep;103(9):1781-1788. doi: 10.1111/aogs.14915. Epub 2024 Jul 16.
10
Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.人乳头瘤病毒基因分型与细胞学分流比较,COMPACT 研究:14642 例女性的设计、方法和基线结果。
Cancer Sci. 2018 Jun;109(6):2003-2012. doi: 10.1111/cas.13608. Epub 2018 May 31.

引用本文的文献

1
Italian guidelines for cervical cancer screening. Multisocietal recommendations on the use of biomarkers in HPV screening with risk-based approach and GRADE methodology.意大利宫颈癌筛查指南。关于在基于风险的人乳头瘤病毒(HPV)筛查中使用生物标志物的多学会建议及分级推荐评估、制定和评价(GRADE)方法
Br J Cancer. 2025 Sep 11. doi: 10.1038/s41416-025-03161-8.
2
Human Papillomavirus and Other Relevant Issues in Cervical Cancer Pathogenesis.人乳头瘤病毒与宫颈癌发病机制中的其他相关问题。
Int J Mol Sci. 2025 Jun 10;26(12):5549. doi: 10.3390/ijms26125549.
3
Adherence to follow-up after the exit cervical cancer screening test at age 60-64: A nationwide register-based study.
60-64 岁时宫颈癌筛查试验结束后的随访坚持情况:一项全国范围内基于登记的研究。
Cancer Med. 2022 Jan;11(1):224-237. doi: 10.1002/cam4.4420. Epub 2021 Nov 12.
4
Discriminating Performance of Early Uterine and Cervical Artery Pulsatility and Resistivity In Pre-Invasive Cervical Lesions.早期子宫和宫颈动脉搏动性及阻力在宫颈上皮内瘤变中的鉴别性能
Sisli Etfal Hastan Tip Bul. 2018 Sep 4;52(3):206-211. doi: 10.14744/SEMB.2018.07769. eCollection 2018.
5
Cervical cancer screening opportunities for Guinea-Bissau.几内亚比绍的宫颈癌筛查机会。
Porto Biomed J. 2017 Nov-Dec;2(6):306-310. doi: 10.1016/j.pbj.2017.03.005. Epub 2017 Apr 18.
6
Clinical Performance of Human Papillomavirus (HPV) Testing versus Cytology for Cervical Cancer Screening: Results of a Large Danish Implementation Study.人乳头瘤病毒(HPV)检测与细胞学检查用于宫颈癌筛查的临床性能:一项丹麦大型实施研究的结果
Clin Epidemiol. 2020 Feb 21;12:203-213. doi: 10.2147/CLEP.S243546. eCollection 2020.
7
HPV Testing for Cervical Cancer in Romania: High-Risk HPV Prevalence among Ethnic Subpopulations and Regions.罗马尼亚的宫颈癌 HPV 检测:不同种族亚人群和地区的高危型 HPV 流行率。
Ann Glob Health. 2019 Jun 20;85(1):89. doi: 10.5334/aogh.2502.
8
HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system.用于宫颈癌筛查的HPV检测:实验室物流的技术改进以及cobas 6800与4800系统相比的良好临床性能
BMC Womens Health. 2019 Mar 25;19(1):47. doi: 10.1186/s12905-019-0743-0.
9
Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.葡萄牙宫颈癌筛查的预算影响分析:细胞学筛查与初级 HPV 筛查策略的比较。
BMC Public Health. 2019 Feb 26;19(1):235. doi: 10.1186/s12889-019-6536-4.
10
Primary cervical screening with high risk human papillomavirus testing: observational study.高危型人乳头瘤病毒检测用于宫颈癌初筛:观察性研究。
BMJ. 2019 Feb 6;364:l240. doi: 10.1136/bmj.l240.